Amylyx Pharmaceuticals
Rating
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
Amylyx Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, primarily focused on creating therapies for amyotrophic lateral sclerosis (ALS) and various other neurodegenerative co...
Latest News
1 day ago · seekingalpha.com
Amylyx Pharmaceuticals, Inc. (AMLX) Discusses LUCIDITY Results and Avexitide Potential in Post-Bariatric Hypoglycemia TranscriptAmylyx Pharmaceuticals, Inc. (AMLX) Discusses LUCIDITY Results and Avexitide Potential in Post-Bariatric Hypoglycemia Transcript
2 days ago · businesswire.com
Amylyx Pharmaceuticals Presents Results from Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia at ObesityWeek® 2026 Annual MeetingCAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals Presents Results from Phase 3 LUCIDITY Clinical Trial of Avexitide in PBH at ObesityWeek® 2026 Annual Meeting.
11 days ago · seekingalpha.com
Amylyx Pharmaceuticals, Inc. (AMLX) Q3 2026 Earnings Call TranscriptAmylyx Pharmaceuticals, Inc. ( AMLX ) Q3 2026 Earnings Call November 5, 2026 8:00 AM EST Company Participants Courtney O'Leary Justin Klee - Co-CEO & Director Camille Bedrosian - Chief Medical Officer Dan Monahan - Chief Commercial Officer James Frates - Chief Financial Officer Joshua Cohen - Co-Founder, Co-CEO & Director Conference Call Participants Jacob Ormes - TD Securities Equity Research Seamus Fernandez - Guggenheim Securities, LLC, Research Division Geoffrey Meacham - Citigroup Inc. Exchange Research Marc Goodman - Leerink Partners LLC, Research Division Michael DiFiore - Evercore ISI Institutional Equities, Research Division Rami Katkhuda - LifeSci Capital, LLC, Research Division James Condulis - Stifel, Nicolaus & Company, Incorporated, Research Division Samuel Lee - Mizuho Securities USA LLC, Research Division Dina Ramadane - BofA Securities, Research Division Ananda Ghosh - H.C. Wainwright & Co, LLC, Research Division Christopher Chen - Robert W.
12 days ago · marketbeat.com
Amylyx Pharmaceuticals Q3 Earnings Call HighlightsAmylyx Pharmaceuticals NASDAQ: AMLX plans to seek U.S. approval for its experimental treatment for post-bariatric hypoglycemia by the end of 2026, as it prepares for a potential launch in 2027 following positive late-stage trial results.
14 days ago · businesswire.com
Amylyx Pharmaceuticals to Participate in Upcoming November Investor ConferencesCAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals to Participate in Upcoming November Investor Conferences.
15 days ago · businesswire.com
Amylyx Pharmaceuticals to Report Third Quarter 2026 Financial Results on November 5, 2026CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals to Report Third Quarter 2026 Financial Results on November 5, 2026.
1 month ago · schaeffersresearch.com
11 Stocks Most Likely to See a Short Squeeze RallyBond yields, oil prices, and inflation rhetoric have teamed up to make it tough for investors heading into earnings season.
1 month ago · businesswire.com
Amylyx Pharmaceuticals to Present Topline Data from Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia at ObesityWeek® 2026 Annual MeetingCAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals to Present Topline Data from Phase 3 LUCIDITY Clinical Trial of Avexitide in PBH at ObesityWeek® 2026 Annual Meeting.
2 months ago · schaeffersresearch.com
10 Stocks With Massive Short Squeeze PotentialBond yields, oil prices, and inflation rhetoric have teamed up to make it tough for investors heading into Q4. Where are short sellers putting their money?
2 months ago · seekingalpha.com
Amylyx Pharmaceuticals, Inc. (AMLX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptAmylyx Pharmaceuticals, Inc. (AMLX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Analyst Summary
Add to Watchlist
Select watchlists to add or remove AMLX